We are looking for wound care experts (m/f/d)

for home care visits in the context of a clinical trial.

Apply now Learn more

Job profile

  • Type of employment: Preferably a fixed-term position at Asklepios Klinik Wandsbek. A freelance arrangement is also possible.
  • Activity: Independent execution of daily dressing changes and wound treatment, accompanied by precise and comprehensive documentation.
  • Location: Initial treatment at Asklepios Wandsbek followed by home visits in the north-east of Hamburg.
  • Employment level:Preferably full time. Part time is possible from a minimum of 60 percent.
  • Remuneration: In accordance with TVöD-K plus a mobility allowance. For freelance work, remuneration is open to negotiation.
  • Start: Desired start in February or March 2026. Planned trial period: April 2026 to September 2027.

Requirements & qualifications

  • Training: Completed qualification as a nurse, nursing specialist, nursing professional, or an equivalent credential.
  • Further training: Certified wound expert (ICW).
  • Experience: Proven practical experience and solid expertise in the field of wound care.
  • Soft skills: Strong patient focus, empathy, and enthusiasm for working with people.
  • Other: High level of mobility, reliability, and flexibility.

What we offer

Competitive remuneration

according to TVöD-K plus a mobility allowance. For the freelance model, negotiable.

Innovative research

Participation in one of the most promising therapeutic approaches to combat Pseudomonas.

Dynamic team

Integration into an experienced and dedicated team of doctors and wound experts.

Many further benefits

such as workplace health promotion and subsidies for pension provision and for the Deutschlandticket.

The clinical trial

Key data of the planned clinical trial with the investigational medicinal product PB-TX-01

Objective
Test the safety and efficacy of the new medicine PB-TX-01.

Patients
Patients with chronic wounds colonized with P. aeruginosa.

Time period
Expected from early April 2026 to mid-2027.

Participants
90 patients in two groups (test group and control group) of 45 people each.

Duration
90 days per patient, including 14 days of treatment phase at the patient’s home.

Tasks
Daily dressing changes, bacterial swabs, photo documentation & treatment.

How the mechanism of action works

Our investigational product has a novel anti-adhesive mechanism of action

1

The PathoBlock active substance (PB-TX-01) is applied topically to the wound.

2

P. aeruginosa virulence factors are deactivated by the active substance.

3

The cells are protected, the biofilm is broken up, and the bacteria are removed.

Our clinical trial team

Join our clinical trial team! These people are already on board.

Asklepios team

Principal investigator

Prof. Dr. med. Christian-Alexander Behrendt

Deputy principal investigator

Dr. med. Artur Besch

Project management

Dagmar Pilz

DK
Study coordinator

Daniela Kühn

Wound expert

Myriam Seifert

?
Wound experts

Additional wound experts (m/f/d)

PathoBlock team

Managing director

Dr. Markus Hannebauer

Inventor & initiator

Prof. Dr. Udo Schumacher (†)

CMC

Dr. Martin Schumacher

Project manager & Regulatory Affairs

Dr. Lena Hänsch

Operations & data management

Dr. Maximilian Schacker

Clinical physician

Dr. Jörn Albring

Apply now!

Become part of our team and help us revolutionize the treatment of chronic wounds.

Go to application Contact us